Reply to ‘The shift of therapeutic strategy for prolactinomas: surgery as the first-line option’

Stephan Petersenn; Maria Fleseriu; Shlomo Melmed

doi:10.1038/s41574-024-00954-4

Reply to ‘The shift of therapeutic strategy for prolactinomas: surgery as the first-line option’

Stephan Petersenn, Maria Fleseriu, Shlomo Melmed

Neurological Surgery

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	311
Number of pages	1
Journal	Nature Reviews Endocrinology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1038/s41574-024-00954-4
State	Accepted/In press - 2024

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1038/s41574-024-00954-4

Cite this

@article{9a3a61079a864d648e1181739cc2dca5,

title = "Reply to {\textquoteleft}The shift of therapeutic strategy for prolactinomas: surgery as the first-line option{\textquoteright}",

author = "Stephan Petersenn and Maria Fleseriu and Shlomo Melmed",

year = "2024",

doi = "10.1038/s41574-024-00954-4",

language = "English (US)",

volume = "20",

pages = "311",

journal = "Nature Reviews Endocrinology",

issn = "1759-5029",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Reply to ‘The shift of therapeutic strategy for prolactinomas

T2 - surgery as the first-line option’

AU - Petersenn, Stephan

AU - Fleseriu, Maria

AU - Melmed, Shlomo

PY - 2024

Y1 - 2024

UR - http://www.scopus.com/inward/record.url?scp=85182823757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85182823757&partnerID=8YFLogxK

U2 - 10.1038/s41574-024-00954-4

DO - 10.1038/s41574-024-00954-4

M3 - Letter

AN - SCOPUS:85182823757

SN - 1759-5029

VL - 20

SP - 311

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

IS - 5

ER -

Reply to ‘The shift of therapeutic strategy for prolactinomas: surgery as the first-line option’

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this